Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.

Automated microscopy and image analysis
Real-time, label free cell analysis
Nano and micro particle analysis

Accelerate to discover
Related topics
Extracellular Vesicle Purity Enhanced by Gen 2 qEV Columns With Customised Proprietary Resin
May 4, 2022
Izon Science has announced the launch of Gen 2, the enhanced range of qEV columns for size-exclusion...
May 3, 2022
A prodigy incorporating a unique combination of patent-pending innovative technologies that takes flow cytometry to the...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Introducing IsoPlexis Single-Cell Natural Killer Panel
Mar 4, 2022
Because of their ability to kill tumour cells, NK cells are an attractive target in cancer immunotherapy, therapeutic...
Enhanced small particle detection on CytekAurora and Northern Lights
Mar 2, 2022
Aurora system with ESP option, can fully resolve particles around 70nm and from the 80nm PS bead. The new violet laser...
Multi-modal PET drives interdisciplinary preclinical imaging
Feb 23, 2022
Preclinical imaging (PCI) plays a vital role in understanding the biological processes behind disease states at the...
Quantitative 3D Optical Imaging for Lago
Feb 21, 2022
Spectral Instrument Imaging just announced a new, strategic partnership with InVivo Analytics, which enables...
Reduces fMRI-BOLD Response in the Brain
Feb 18, 2022
fMRI studies often involve the electrical stimulation of i.e. the forepaw, detecting where this stimulation is...
Mar 20, 2020
During metastasis cancer cells are exposed to potentially destructive hemodynamic forces including fluid shear stress (FSS) while en route to distant sites. However, prior work indicates that cancer cells are more resistant to brief pulses of high-level fluid shear stress (FSS) in vitro relative to non-transformed epithelial cells. Herein we identify a mechanism of FSS resistance in cancer cells, and extend these findings to mouse models of circulating tumor cells (CTCs). We show that cancer cells acutely isolated from primary tumors are resistant to FSS. Our findings demonstrate that cancer cells activate the RhoA-myosin II axis in response to FSS, which protects them from FSS-induced plasma membrane damage. Moreover, we show that the myosin II activity is protective to CTCs in mouse models. Collectively our data indicate that viable CTCs actively resist destruction by hemodynamic forces and are likely to be more mechanically robust than is commonly thought.
Related technologies: Fluorescence, luminescence, X-ray, radiographic imaging
Get more info
Brand profile
Spectral Instruments Imaging manufactures instruments for preclinical optical (bioluminescent, fluorescent) and X-ray imaging.
More info at:
https://spectralinvivo.com/